ASN's Mission

To create a world without kidney diseases, the ASN Alliance for Kidney Health elevates care by educating and informing, driving breakthroughs and innovation, and advocating for policies that create transformative changes in kidney medicine throughout the world.

learn more

Contact ASN

1401 H St, NW, Ste 900, Washington, DC 20005


The Latest on Twitter

Kidney Week

Abstract: TH-PO509

Efficacy and Safety of Initial Pulse Methylprednisolone Treatment in Renal Sarcoidosis: A Randomized Trial

Session Information

Category: Chronic Kidney Disease (Non-Dialysis)

  • 305 CKD: Clinical Trials and Tubulointerstitial Disorders


  • Boffa, Jean-Jacques, Tenon Hospital, AP-HP, Paris, France
  • Mahevas, Matthieu, AP-HP, UPEC UNIVERSITY, Paris, France
  • Daugas, Eric, Bichat hospital, AP-HP, Paris, France
  • Guerrot, Dominique, Rouen University Hospital, Rouen, France
  • Delahousse, Michel, FOCH Hospital, Suresnes, France
  • Simon, Tabassome, Assistance Publique -Hôpitaux de Paris, Paris, France
  • Vrigneaud, Laurence, hospital, Valenciennes , France
  • Krastinova, Evguenia, Creteil Hospital, Créteil, France
  • Pillebout, Evangeline, Hopital Saint-Louis, Paris, France
  • Audard, Vincent, Mondor Hospital, AP-HP, Paris, France
  • Verhelst, David, None, PARIS, France
  • Valeyre, Dominique, Avicenne Hospital AP-HP, Bobigny, France

Group or Team Name

  • Corticoïdose Group

Sarcoidosis tubulo-interstitial nephritis (STIN) induces severe renal insufficiency with poor outcome. Despite treatment with steroids, most patients develop chronic kidney disease. Pulse methylprednisolone treatment has been used to improve renal function but this therapeutic strategy has never been evaluated. We assessed whether initial pulse methylprednisolone is effective and safe at improving renal function compared to oral steroids at 3 months of follow-up.


In a multicenter randomized open control trial, in patients with proven acute sarcoidosis tubulo-interstitial nephritis, we randomly assigned forty patients with STIN to receive pulse methylprednisolone 15 mg/kg/day for three days and per os steroids afterwards (group A) or per os 1 mg/kg/d steroids from the start (group B). The primary outcome was CKD-EPI estimated glomerular filtration rate (eGFR) during the follow-up. The primary efficacy end point was the percentage of patients having a positive response at 3 months of follow-up, defined by an improvement of more than 100% of eGFR compared to eGFR before treatment or eGFR ≥ 60 ml/min/1.73m2. Secondary end points included side effects of steroids.


The mean age of the trial participants was 59 (45-68) years and 70% were men. Among 40 participants, only one patient was excluded for a misdiagnosis of tuberculosis. Baseline eGFR before treatment were 25(22-37) ml/min/1.73m2 for group A and 22(17-40) ml/min/1.73m2 for group B, p=0.3. In the intent-to-treat population, the median eGFR was 45(39-64) ml/min/1.73m2 for group A and 45(34-73) ml/min/1.73m2 for group B at 3 months. Patients randomized to pulse methylprednisolone were significantly less likely to achieve the primary efficacy end point: 10 of 20 (50%) vs 16 of 20 (80%), p=0.047. eGFR were similar between groups after 1 month of treatment. No participants presented cardiac arrhythmia or conduction disorder during pulse methylprednisolone. Number of adverse effects was similar between groups: 15 in group A and 14 in group B.


Among patients with acute STIN, pulse methylprednisolone treatment was not significantly different from oral steroids in improving renal function at three months follow-up.


  • Government Support - Non-U.S.